Plasmablastic lymphoma exclusively involving bones mimicking osteosarcoma in an immunocompetent patient
A case report

Azmal Kabir Sarker, MD\textsuperscript{a,b,c}, Hyung-Jun Im, MD, PhD\textsuperscript{a,d}, Jin Chul Paeng, MD, PhD\textsuperscript{a}, Gi Jeong Cheon, MD, PhD\textsuperscript{a,e,f}, Keon Wook Kang, MD, PhD\textsuperscript{a,e}, June-Key Chung, MD, PhD\textsuperscript{a,e}, Dong Soo Lee, MD, PhD\textsuperscript{a,d}

1. Introduction

Plasmablastic lymphoma (PBL), according to the World Health Organization (WHO)'s classification 2008, is characterized by diffuse proliferation of large neoplastic cells that has a morphologic resemblance to B immunoblasts with immunophenotype of plasma cells.\cite{1} Immunophenotyping is the favored technique for a definite diagnosis since the first case of PBL was reported.\cite{2} There has been a number of reports of PBL that occurred predominantly in adult males who are immuno-compromised due to human immunodeficiency virus (HIV) infection or due to solid organ transplantation with a predilection for soft tissue of oral cavity or in the vicinity.\cite{3,4} However, its occurrence is increasingly being reported in immunocompetent individuals and also in osseous and extra-oral sites.\cite{3,5-8} It is observed that there is less frequent association of extraoral PBL with HIV.\cite{9,10} There are several reported cases of PBL with extraoral and osseous manifestation in addition to soft tissue PBL in immuno-competent patient.\cite{3,5-8} No case has yet been reported PBL arising exclusively from osseous tissue in an immunocompetent person. We report a case of PBL that was confirmed by immunohistochemistry (IHC) from the biopsy of lesions from 2 separate biopsy sites revealed features of PBL.

Keywords: case report, FDG, osteosarcoma, PET/CT, plasmablastic lymphoma, skull

Abstract

Background: It has been known that plasmablastic lymphoma (PBL) is a neoplasm of immunocompromised patients occurring in soft tissue of oral cavity or in the vicinity whereas bone is an unlikely site to harbor PBL. However, its occurrence is increasingly being reported in immunocompetent individuals in either osseous or extra-oral sites. To our best knowledge, F-18 FDG PET/CT findings of PBL involving bones in an immunocompetent patient have not been reported, yet.

Case summary: We report a case of PBL involving multiple bones in an immunocompetent patient. Features of different imaging modalities including F-18 Fluoro-deoxy glucose (FDG) positron emission tomography/computed tomography (PET/CT) were correlated well as findings of osteosarcoma in mandible with metastatic lesions. However, the histopathology and immunohistochemistry (IHC) of bone tissues from 2 separate biopsy sites revealed features of PBL.

Conclusion: awareness to F-18 FDG PET/CT findings of PBL involving bones in an immunocompetent patient may prevent misdiagnosis.

Abbreviations: CD = cluster of differentiation, FDG = fluorodeoxyglucose, HHV = human herpes virus, HIV = human immunodeficiency virus, IHC = immunohistochemistry, Ki 67 = antigen Ki 67, a marker of proliferation, LANA 1 = latency-associated nuclear antigen, MDP = methyl diphosphonate, MRI = magnetic resonance imaging, PBL = plasmablastic lymphoma, PET/CT = positron emission tomography/computed tomography, PNS = paranasal sinus, SUV = standard uptake value, T2W = T2 weighted, WHO = World Health Organization.
lesion. Ultrasound of mandibular mass showed a mixed echogenic mass with minimal Doppler flow. Magnetic resonance imaging (MRI) of Paranasal sinus (PNS) (Fig. 2) showed soft tissue mass involving right mandibular ramus, angle, posterior part of body, and surrounding masticator space with T2-weighted (T2W) iso to slightly low-signal intensity, homogeneous enhancement, and sunburst periosteal reaction. MRI also revealed another soft tissue mass involving right supero-posterior parietotemporal bone. In addition, there was also diffuse infiltrative change in the subcutaneous spaces of the right neck which were more likely to be due to inflammatory change rather than tumor infiltration. A few indeterminate lymph nodes in level II on the right side were also noted.

PET/CT (Fig. 3) revealed hypermetabolic lesion on the right side of mandible with increased FDG uptake along periosteal reaction with maximum Standard Uptake Value (SUV) of 4.0. The mandibular lesion showed a sunburst appearance on CT. The lesion in right parietal bone was hypermetabolic with a maximum SUV of 3.02. In addition, hypermetabolic lesions were also seen in right scapula and left 9th rib with maximum SUV being 2.89 and 3.07, respectively. The lesion in right parietal bone including other 2 in scapula and rib appeared osteolytic on CT images. Skeletal scintigraphy (Fig. 4) showed increased Tc-99m-methyl diphosphonate (MDP) uptake in the mandible, right parietal bone, right scapula, and left 9th rib.

Based on the imaging findings osteosarcoma of mandible with multiple metastases in parietal bone, scapula and rib were the most likely differential diagnosis. Biopsy specimen from mandible and parietal bone lesions were taken for histopathological examination. The histopathology and IHC features of both tumors were compatible with plasmablastic lymphoma; HIV serology in the patient was negative.

In situ hybridization of the tumor cells revealed most of the cells to be positive for Epstein Burr virus. Human herpes virus (HHV)-8 latency-associated nuclear antigen (LANA 1) was found negative. IHC of the tumor cell revealed their positivity for Cluster of differentiation (CD) 38, CD138 and CD79a. Ki67 antigen was also positive in 20% tumor cells. The tumor cells were found to be negative for CD45, CD56, and CD20. These features were compatible with the WHO criteria 2008 for PBL.

Patient was then treated with chemotherapy in the protocol of non-Hodgkin’s lymphoma for the treatment of PBL.
3. Materials and methods

Approval from institutional review board of Seoul National University Hospital was obtained.

4. Discussion

In this current case, an initial differential diagnosis of osteosarcoma was made based on hybrid imaging. The reason for this was high FDG uptake on PET combined with classic feature of osteosarcoma, sunburst appearance, in mandible. Patient’s age and site of lesion were also compatible with the diagnosis. The immuno-competent state of the person prevented the clinical minds to think about PBL. Also compatible with the existing knowledge of tumor metabolism, osteosarcoma like most other malignancies demonstrates increased FDG uptake on PET images. Osteosarcoma and other malignant bone lesions tend to have SUV of >2. Some recent case series reports SUV of osteosarcoma ranging from 3.15 to 16.5. Remarkable FDG uptake is reported in osteolytic bone metastases which is compatible with the fact that lesions in parietal bone, scapula, and rib appeared osteolytic on CT images while demonstrating increase FDG uptake on PET. However, there are reports of bone

Figure 3. F-18 FDG PET/CT: hypermetabolic lesion on the right side of mandible, with sunburst appearance and increased FDG uptake along the periosteal reaction. Hypermetabolic lesions in the right parietal bone and right scapula. FDG = fluorodeoxyglucose, PET/CT = positron emission tomography/computed tomography.
metastases from osteosarcoma that displayed low uptake of FDG on PET scan\textsuperscript{17} or was false negative.\textsuperscript{18}

In the current case, all 4 bone lesions were hypermetabolic with maximum SUV between 3 and 4. There are few reported cases of soft tissue PBL with hypermetabolic activity on PET images\textsuperscript{6,19,20}. Cazaentre et al\textsuperscript{21} reports a case of soft tissue PBL showing no abnormal FDG uptake but associated hypermetabolism in retroperitoneal lymph node with SUV of 7.5.

CT images of the current case showed that among the bone lesions the 1 in mandible was osteoblastic whereas the other 3 were osteolytic. In the reported cases of PBL either the lesions themselves have osteolytic appearance on CT scan\textsuperscript{21–23} or there was CT evidence of osteolysis adjacent to soft tissue lesions.\textsuperscript{6,21,22,24–26}

Though there is a report of osteolytic appearance of PBL on bone scan\textsuperscript{22} in this current case, concordant with the FDG uptake on PET images, bone scan demonstrated increased MDP uptake in all 4 bone lesions.

5. Conclusion

The present case reports F-18 FDG PET/CT findings of a case of PBL arising in bone in an immunocompetent patient. Although the definite diagnosis of PBL is reliant on IHC, awareness to possible diverse finding on PET/CT images can prevent misdiagnosis.

References

\textsuperscript{[1]} Swerdlow SHCE, Harris NL, Jaffe ES, Pilcer SA, Stein H, Thiele J, Vardiman JW. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4TH edn. Lyon, France:International Agency for Research on Cancer; 2008. 256–7.

\textsuperscript{[2]} Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997;89:1413–20.

\textsuperscript{[3]} Rafaniello Raviele P, Pruneri G, Maiorano E. Plasmablastic lymphoma: a review. Oral Dis 2009;15:38–45.

\textsuperscript{[4]} Castillo JJ, Reagan JL. Plasmablastic lymphoma: a systematic review. Scientific World J 2011;11:687–96.

\textsuperscript{[5]} Kim JE, Kim YA, Kim WY, et al. Human immunodeficiency virus-negative plasmablastic lymphoma in Korea. Leuk Lymphoma 2009;50:582–7.

\textsuperscript{[6]} Saraceni C, Agostino N, Cornfield DB, et al. Plasmablastic lymphoma of the maxillary sinus in an HIV-negative patient: a case report and literature review. Springerplus 2013;2:142.

\textsuperscript{[7]} Colomo L, Loong F, Rives S, et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol 2004;28:736–47.

\textsuperscript{[8]} Teruya-Feldstein J, Chiao E, Filippa DA, et al. CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients. Ann Oncol 2004;15:1673–9.

\textsuperscript{[9]} Hansca D, Montague N, Stefanovic A, et al. Oral and extranodal plasmablastic lymphoma: similarities and differences in clinico-pathologic characteristics. Am J Clin Pathol 2010;134:710–9.

\textsuperscript{[10]} Dorwal P, Sachdev R, Mishra P, et al. Extranodal plasmablastic lymphoma detected using ascitic fluid cytology and flow cytometry: a case report with a review of the literature. Acta Cytologica 2014;58:309–17.

\textsuperscript{[11]} Baert ALKM. Medical Radiology Diagnostic Imaging. Berlin:Springer; 2009. 278.

\textsuperscript{[12]} Hoh CK, Hawkins RA, Glaspy JA, et al. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose. J Comput Assisted Tomogr 1993;17:582–9.

\textsuperscript{[13]} Tian M, Zhang H, Endo K. Comparison of cell proliferation, protein, and glucose metabolism in musculoskeletal tumors in a PET study. J Biomed Biotechnol 2011;2011:807929.

\textsuperscript{[14]} Im HJ, Kim TS, Park SY, et al. Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma. Eur J Nucl Med Mol Imaging 2012;39:39–49.

\textsuperscript{[15]} Nakai T, Okuyama C, Kubota T, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2003;32:1253–8.

\textsuperscript{[16]} Yang HL, Lin T, Wang XM, et al. Diagnosis of bone metastases: a meta-analysis comparing (1)8F FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 2011;21:2604–17.

\textsuperscript{[17]} Frantzus C, Scnk J, Daldrup-Link HE, et al. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 2000;27:1305–11.

\textsuperscript{[18]} Shreve PD, Grossman HB, Gross MD, et al. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 1996;199:751–6.

\textsuperscript{[19]} Davison JM, Subramaniam RM, Surasi DS, et al. FDG PET/CT in patients with HIV. Am J Roentgenol 2011;197:284–94.
[20] Treglia G, Paone G, Stathis A, et al. An unusual case of plasmablastic lymphoma presenting as paravertebral mass evaluated by (18) F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2014;48:89–90.
[21] Cazaentre T, Sanhes L, Laurent G, et al. Interesting image. Assessment of plasmablastic lymphoma by F-18 FDG PET/CT: case report. Clin Nucl Med 2010;35:882–3.
[22] Jenabi A, Mooraki A, Jabbari M, et al. Multifocal cranial plasmablastic lymphoma as a rare manifestation of posttransplant lymphoproliferative disorder. Iran J Kidney Dis 2012;6:380–5.
[23] Mondal SK, Bera H, Biswas PK, et al. High-grade plasmablastic neoplasm of humerus in an HIV-negative patient, which was indeterminate between plasmablastic lymphoma and plasmablastic myeloma. J Cancer Res Ther 2011;7:214–6.
[24] Degnan AJ, Levy LM. Orbital plasmablastic lymphoma with remission following chemotherapy. J Radiol Case Rep 2011;5:1–7.
[25] Schepel MA, Nikitakis NG, Fernandes R, et al. Oral plasmablastic lymphoma in an HIV-negative patient: a case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;100:198–206.
[26] Gogia A, Balhshy S. Plasmablastic lymphoma of oral cavity in a HIV-negative child. Pediatr Blood Cancer 2010;55:390–1.